Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
10 hedge funds and large institutions have $81M invested in Verona Pharma in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
76% more capital invested
Capital invested by funds: $46.1M → $81M (+$35M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
11% more funds holding
Funds holding: 9 → 10 (+1)
1.26% more ownership
Funds ownership: 3.77% → 5.03% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$10.4M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.3M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$1M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.63K |
| 5 |
Morgan Stanley
New York
|
+$185 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$873K |
| 2 |
Jane Street
New York
|
-$133K |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$62.7K |
VRNA Hedge Fund Activity: Q3 2017 in Review
10 of the 4,006 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2017, worth a combined $81M — up 76% from $46.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VRNA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Vivo Capital, adding an estimated $10.4M. The largest seller was Fidelity International, exiting entirely with an estimated $873K sold.
- 10 institutional investors held Verona Pharma (VRNA) as of Q3 2017, up from 9 in Q2 2017.
- Funds reported $81M of Verona Pharma stock for Q3 2017, up 76% quarter-over-quarter.
- 3 funds opened new Verona Pharma positions in Q3 2017 and 2 closed out, a net change of +1 holder.
- The largest Verona Pharma buyer in Q3 2017 was Vivo Capital, an estimated $10.4M added.
- The largest Verona Pharma seller in Q3 2017 was Fidelity International, an estimated $873K sold.
Based on aggregated 13F filings for Q3 2017.